Premium
Propranolol‐resistant infantile hemangioma successfully treated with sirolimus
Author(s) -
DávilaOsorio Victoria L.,
Iznardo Helena,
Roé Esther,
Puig Lluis,
Baselga Eulalia
Publication year - 2020
Publication title -
pediatric dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 73
eISSN - 1525-1470
pISSN - 0736-8046
DOI - 10.1111/pde.14163
Subject(s) - propranolol , medicine , sirolimus , hemangioma , prednisolone , infantile hemangioma , discovery and development of mtor inhibitors , vascular tumors , surgery , pi3k/akt/mtor pathway , apoptosis , biochemistry , chemistry
Infantile hemangiomas are the most common benign vascular tumors in childhood. Propranolol is the first‐line treatment for infantile hemangiomas, but failures may occur. Sirolimus, an mTOR inhibitor, is a promising drug for the treatment of vascular malformations and vascular tumors. We present the case of a child with multiple infantile hemangiomasthat was successfully treated with sirolimus and propranolol after failure of combined propranolol and prednisolone treatment.